Abstract RF6-01: Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2-positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Samsung Medical Center, Sungkyunkwan University, Fudan University, Fudan University Shanghai Cancer Center, National Taiwan University Hospital, Hospital São Lucas da PUCRS, Pontifícia Universidade Católica do Rio Grande do Sul, Cleveland Clinic, Hospital Clínic de Barcelona, Tokai University, Tokai University Hospital, Helios Hospital Berlin-Buch, Seoul National University, Seoul National University Hospital, First Hospital of Jilin University, Peking University Cancer Hospital, Shandong Tumor Hospital, Shandong First Medical University, Sun Yat-sen Memorial Hospital, Asan Medical Center, Daiichi Sankyo (United States), University of Pittsburgh, UPMC Hillman Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129371541